New Trends in (Bio)chemical Engineering: Biobased Pharmaceutical Processes

A special issue of ChemEngineering (ISSN 2305-7084).

Deadline for manuscript submissions: 31 October 2025 | Viewed by 510

Special Issue Editors


E-Mail Website
Guest Editor
1. Faculty of Biotechnology, The University of Agronomic Sciences and Vetrinary Medicine of Bucharest, 59 Blvd Marasti, 1th District, 011464 Bucharest, Romania
2. Biotechnology Department, The National Institute of Chemistry and Petrochemistry R&D of Bucharest, 202 Splaiul Independentei, 6th District, 060021 Bucharest, Romania
Interests: bioactive compound derived from microbial vegetal or animal resources; biological properties of major or specific compounds; in silico biological properties, in vitro and in vitro biological activities
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
National Institute of Chemical-Pharmaceutical Research and Development—ICCF, 112 Vitan Av., 3th District, 031299 Bucharest, Romania
Interests: pharmaceutical biotechnology; property modeling; molecular docking; DFT computations
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pharmaceuticals derived from plant, microbial, or animal biomass could shape the future of the bioeconomy, particularly in an era where the rise of oncological diseases and microbial resistance presents significant challenges. The development of new pharmaceutical technologies using various types of biomasses as raw materials offers a sustainable approach that reduces the carbon footprint and minimises environmental impact. Microbial fermentation and synthetic biology are revolutionising bioproduct manufacturing, enabling the efficient and scalable production of therapeutic compounds. In this process, computational methods, mathematical modelling, and artificial intelligence accelerate molecular screening and enhance the prediction of bioavailability, toxicity, and efficacy with greater precision.

In this regard, manuscripts covering, but not limited, the following topics are welcome:

  1. Artificial intelligence (AI) and computational methods applied to predicting molecular interactions, bioavailability, toxicity, and biological activities—such as antimicrobial or antitumour properties—of specific biomolecules, followed by in vitro or in vivo studies that validate or invalidate AI-driven or computational results;
  2. The development of sustainable biopharmaceuticals using plant, microbial, or cell-culture-derived biomaterials with potential medical applications;
  3. Nanomaterials with pharmaceutical or phytopharmaceutical potential, with properties validated through in vitro or in vivo studies;
  4. Mathematical models used to predict the behaviour of biological processes based on data obtained from in vitro or in vivo studies;
  5. Process optimisation and management programmes applied to optimising microbial fermentation-based bioproducts with pharmaceutical potential.

Dr. Nicoleta Nicole Radu
Dr. Amalia Stefaniu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. ChemEngineering is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • in silico screening
  • in vitro and/or in vivo tests
  • math models and/or artificial intelligence applied to (bio)chemical processes optimization

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 1490 KiB  
Review
Liposome-Based Drug Delivery Systems: From Laboratory Research to Industrial Production—Instruments and Challenges
by Suman Basak and Tushar Kanti Das
ChemEngineering 2025, 9(3), 56; https://doi.org/10.3390/chemengineering9030056 - 27 May 2025
Viewed by 308
Abstract
Liposome-based drug delivery systems have revolutionized modern pharmaceutics, offering unparalleled versatility and precision in therapeutic delivery. These lipid vesicles, capable of encapsulating hydrophilic, hydrophobic, and amphiphilic drugs, have demonstrated significant potential in addressing pharmacokinetic challenges such as poor solubility, systemic toxicity, and rapid [...] Read more.
Liposome-based drug delivery systems have revolutionized modern pharmaceutics, offering unparalleled versatility and precision in therapeutic delivery. These lipid vesicles, capable of encapsulating hydrophilic, hydrophobic, and amphiphilic drugs, have demonstrated significant potential in addressing pharmacokinetic challenges such as poor solubility, systemic toxicity, and rapid clearance. This review provides a comprehensive exploration of the evolution of liposomes from laboratory models to clinically approved therapeutics, highlighting their structural adaptability, functional tunability, and transformative impact on modern medicine. We discuss pivotal laboratory-scale preparation techniques, including thin-film hydration, ethanol injection, and reverse-phase evaporation, along with their inherent advantages and limitations. The challenges of transitioning to industrial-scale production are examined, with emphasis on achieving batch-to-batch consistency, scalability, regulatory compliance, and cost-effectiveness. Innovative strategies, such as the incorporation of microfluidic systems and advanced process optimization, are explored to address these hurdles. The clinical success of Food and Drug Administration (FDA)-approved liposomal formulations such as Doxil® and AmBisome® underscores their efficacy in treating conditions ranging from cancer to fungal infections. Furthermore, this review delves into emerging trends, including stimuli-responsive and hybrid liposomes, as well as their integration with nanotechnology for enhanced therapeutic precision. As liposomes continue to expand their role in gene therapy, theranostics, and personalized medicine, this review highlights their potential to redefine pharmaceutical applications. Despite existing challenges, ongoing advancements in formulation techniques and scalability underscore the bright future of liposome-based therapeutics in addressing unmet medical needs. Full article
Show Figures

Figure 1

Back to TopTop